Keyphrases
Academic Medical Centers
11%
Antibiotics
15%
Antimicrobial
19%
Antimicrobial Stewardship
15%
Antimicrobial Stewardship Program
12%
Antimicrobial Use
22%
Asia
14%
Bacteremia
24%
Bloodstream Infection
33%
Burn Patients
14%
Catheter
11%
Catheter-related Bloodstream Infection (CRBSI)
24%
Centers for Disease Control
11%
Chlorhexidine
15%
Clinical Characteristics
11%
Clinical Outcomes
11%
Confidence Interval
20%
Diagnostic Criteria
14%
Disease Prevention
11%
Elderly Patients
14%
Enterococcus
14%
External Ventricular Drain
14%
H. Influenzae Type b
14%
Haemophilus Influenzae Type b
14%
Health Systems
13%
Healthcare Facilities
11%
Healthcare Workers
18%
Hemodialysis
17%
Hospital-acquired
14%
Infection Prevention
12%
Infection-related Ventilator-associated Complications
12%
Infectious Diseases Consultation
27%
Meningitis
18%
Mupirocin
12%
New York City
25%
Risk Factors
24%
Skin Tissue
14%
Soft Tissue Infection
14%
Staphylococcus Aureus
14%
Surgical Site Infection
14%
Telavancin
14%
Tertiary Care Hospital
14%
Thailand
14%
Trauma Patients
14%
Vancomycin
11%
Vancomycin-resistant Enterococci
18%
Ventilator Support
12%
Ventilator-associated
17%
Ventilator-associated Pneumonia
23%
Worse Outcome
14%
Medicine and Dentistry
Acute Cholecystitis
7%
Antibiotic Prophylaxis
8%
Antibiotics
9%
Antifungal Agent
10%
Antifungal Medication
7%
Antiinfective Agent
17%
Antivirus Agent
7%
Bloodstream Infection
32%
Cancer Treatment
7%
Candidemia
9%
Catheter Infection
21%
Chlorhexidine
10%
Clinical Management
7%
Clostridium Difficile Infection
7%
Consultation
11%
COVID-19
11%
Diagnosis
14%
Disease
15%
Enterococcus
7%
Esthetic Surgery
7%
External Ventricular Drain
14%
Fusobacterium
7%
Hand Hygiene
7%
Health Care
16%
Health Care Facility
7%
Healthcare Associated Infection
7%
Infection
100%
Infection Prevention
11%
Infection Rate
10%
Infectious Disease
14%
Injury
14%
Intensive Care Unit
14%
Isoniazid
7%
Klebsiella pneumoniae
8%
Mantoux Test
7%
Prevalence
12%
Prophylaxis
7%
Prospective Study
8%
Pseudomonic Acid
14%
Randomized Controlled Trial
8%
Respiratory Failure
7%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Soft Tissue Infection
14%
Staphylococcus Aureus
19%
Systematic Review
7%
Tertiary Care
14%
Thermal Burn
14%
Thrombophlebitis
7%
Vancomycin
8%
Ventilator-Associated Pneumonia
23%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Cholecystitis
7%
Acute Kidney Failure
7%
Antibiotic Prophylaxis
7%
Antibiotics
12%
Antifungal Agent
13%
Antiinfective Agent
26%
Antivirus Agent
5%
Bacterial Endocarditis
7%
Bloodstream Infection
28%
Brain Ventriculitis
7%
Candidemia
7%
Catheter Infection
15%
Cohort Study
8%
Coronavirinae
7%
Disease
12%
Diseases
16%
End Stage Renal Disease
6%
Enterococcal Infection
7%
Escherichia coli
9%
Haemophilus influenzae
14%
Hemodialysis
16%
Heparin
7%
Infection
75%
Injury
7%
Invasive Aspergillosis
7%
Invasive Candidiasis
7%
Isoniazid
7%
Klebsiella pneumoniae
8%
Malignant Neoplasm
7%
Meningitis
17%
Neurocysticercosis
7%
Prospective Study
7%
Quinolone Derivative
14%
Randomized Controlled Trial
7%
Respiratory Failure
7%
SARS Coronavirus
7%
Surgical Infection
7%
Systemic Mycosis
7%
Taurolidine
7%
Telavancin
14%
Thrombophlebitis
7%
Tuberculin
7%
Vancomycin
14%
Vancomycin Intermediate Staphylococcus Aureus
7%
Vancomycin-Resistant Enterococcus
10%
Ventilator Associated Pneumonia
7%